
Ozempic Shows Lower Heart Risk Than Mounjaro
Xurve View
Insights:
Xurve View

NOVO NORDISK A/S-B reported that its diabetes drug Ozempic delivered a 6% lower risk of cardiovascular events compared to rival treatments. The findings emerged during a Tuesday presentation in Italy at a major medical gathering. The data arrives as drug makers vie for market share in the United States obesity sector.







